Role of surgery in ovarian cancer: An updateVERGOTE, I.Acta chirurgica Belgica. 2004, Num 3, pp 246-256, issn 0001-5458, 11 p.Article

DYSGERMINOMA OF THE OVARY IN ASSOCIATION WITH XY GONADAL DYSGENESISVERGOTE I; DIELEMAN V; BECQUART D et al.1983; EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY; ISSN 0301-2115; NLD; DA. 1983; VOL. 14; NO 6; PP. 385-391; BIBL. 20 REF.Article

Quality of life in patients receiving treatment for gynecologic malignancies: Special considerations for patient careWENZEL, L; VERGOTE, I; CELLA, D et al.International journal of gynecology & obstetrics. Supplement. 2003, Vol 83, Num 1, pp 211-229, issn 0924-8447, 19 p.Article

Endocrine Treatment and Prevention of Breast and Gynaecological Cancers. 3rd Biennial International Meeting of the Flemish Gynaecological Oncology GroupVERGOTE, I; NEVEN, P.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, issn 1359-6349, 99 p.Conference Proceedings

An update on non-gynaecological effects of SERM's and aromatase inhibitorsNETELENBOS, C.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S63-S64, issn 1359-6349Conference Paper

Tamoxifen for primary breast cancer prevention in BRCA heterozygotesROBSON, M.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S18-S19, issn 1359-6349Conference Paper

Detection of the oestrogen receptor (ER) : immunohistochemical versus cytosol measurementsLEAKE, R.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S18-S19, issn 1359-6349Conference Paper

Oestrogen receptor determination in breast and gynaecological tissue. What is the best approach to reproducible measurement?LEAKE, R.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S33-S34, issn 1359-6349Conference Paper

Arzoxifene in breast cancerCHAN, S.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S55-S56, issn 1359-6349Conference Paper

Faslodex (ICI 182780) : an oestrogen receptor downregulatorHOWELL, A.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S87-S88, issn 1359-6349Conference Paper

Soyfoods and soybean phyto-oestrogens (isoflavones) as possible alternatives to hormone replacement therapy (HRT)MESSINA, M.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S71-S72, issn 1359-6349Conference Paper

Taximoxifen and the uterus: potential uterine risks of anti-oestrogensVERGOTE, I; NEVEN, P.European journal of cancer. Supplement (1990). 1998, Vol 34, Num 4, issn 1359-6349, 71 p.Conference Proceedings

A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastasesHOWELL, A; ROBERTSON, J. F. R; VERGOTE, I et al.Breast cancer research and treatment. 2003, Vol 82, Num 3, pp 215-222, issn 0167-6806, 8 p.Article

New SERMs in developmentNEVEN, P.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S26-S27, issn 1359-6349Conference Paper

Selective oestrogen receptor downregulatorHOWELL, Anthony.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S61-6S2, issn 1359-6349Conference Paper

An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancerBUZDAR, A.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S82-S84, issn 1359-6349Conference Paper

Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experienceJONAT, W.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S39-S40, issn 1359-6349Conference Paper

Oestrogen and female cancers : the past 100 yearsNEVEN, P.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S13-S14, issn 1359-6349Conference Paper

Gastrostomy using a Gastrofix as an alternative for nasogastric tubes in ovarian cancer surgeryAMANT, F; BERTELOOT, P; VERGOTE, I et al.Gynecologic oncology (Print). 1998, Vol 71, Num 3, pp 348-351, issn 0090-8258Article

A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomasTROPE, C; KAERN, J; VERGOTE, I et al.Cancer chemotherapy and pharmacology. 1990, Vol 26, pp S45-S47, issn 0344-5704, SupplConference Paper

Radio-immunotargeting in experimental animal models of intraperitoneal cancerFJELD, J. G; VERGOTE, I; DE VOS, L et al.Acta obstetricia et gynecologica Scandinavica. Supplement. 1992, Vol 71, Num 155, pp 105-111, issn 0300-8835Conference Paper

An update on non-uterine gynaecological effects on raloxifeneGOLDSTEIN, S. R.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S65-S66, issn 1359-6349Conference Paper

Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriersREBBECK, T. R.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 6, pp S15-S17, issn 1359-6349Conference Paper

New insights in oestrogen receptor (ER) research : the ERβGUSTAFSSON, J.-A.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, issn 1359-6349, p. S16Conference Paper

Clinico-pharmacological aspects of different hormone treatmentsLØNNING, P. E.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 4, pp S81-S82, issn 1359-6349Conference Paper